S U MMARY The effects of oxpentifylline were assessed in a double blind trial in 11 patients with Parkinson's disease already under treatment. No significant improvement was noted. Eight patients developed involuntary movements or a worsening of movements if already present. The significance of this unexpected finding is discussed.
The modern treatment of Parkinson's disease is with drugs aimed at enhancing dopaminergic activity in the striatum. There is evidence that there are two types of dopamine "receptor" and that one receptor is dependent on cyclic AMP (adenosine 3'5' monophosphate) which acts as a "second messenger."''-3 The precise role and importance of the two dopamine receptors in Parkinson's disease and in the receptor hypersensitivity phenomena that complicate treatment is at present uncertain but compounds which affect dopamine receptor sensitivity are of great interest and might introduce new possibilities in the management of patients with Parkinson's disease.
Inhibition of cyclic AMP phosphodiesterase raises the intracellular levels of cyclic AMP and should therefore enhance dopaminergic activity. Some experimental work in animals has supported this hypothesis4 5 although no enhancement of therapeutic benefit was found in patients treated with caffeine (which is a moderate phosphodiesterase inhibitor) and the dopamine agonist bromocriptine. 6 Arbuthnott and his colleagues7 showed that aminophylline potentiated the effects of apomorphine-induced turning in a denervation animal model (6-hydroxydopamine lesioned rats) but concluded that, as this was the only central stimulant amongst the drugs they tested, the effects observed were related to the known central stimulatory actions of aminophylline rather than to its phosphodiestrase inhibitory activity.
Oxpentifylline is a methylxanthine derivative related to theophylline. This is a widely used group of pharmacological agents of which oxpentifylline is the most recent addition. It treatment. Criteria for inclusion in the trial were "on-off" attacks, unsatisfactory response to levodopa or deterioration while on levodopa following an initial improvement. On admission to the trial all patients continued on their current therapy of levodopa alone, levodopa plus a decarboxylase inhibitor (Sinemet), anticholinergics (either benzhexol or orphenadrine), bromocriptine or a combination of these agents. The study had the consent of the ethics committee and the purpose of the trial was explained fully to all patients who were asked to participate. Patients with significant renal, hepatic or ischaemic heart disease were excluded.
The study was designed as a double-blind, within-patient comparison of oxpentifylline and placebo added to their existing therapy. Before entering the trial each patient was assessed using the rating scale previously described.12 Oxpentifylline in large doses has been associated with upper gastrointestinal side effects, notably nausea and epigastric discomfort. All patients were therefore initially titrated to a maximum tolerated dose, up to 1200 mg a day in divided doses, over the course of two to six weeks. Patients were then randomly allocated to treatment with either oxpentifylline, in the maximum dose achieved, or placebo. The drugs were presented in film coated tablets matched for size, shape and colour and patients took each drug for six weeks and were then crossed over to the alternative treatment.
The patients were assessed at two-weekly intervals by two independent observers, one (RGA) "blind" who completed the clinical assessment and the other (JAT) who undertook the routine supervision of patients and recorded any adverse effects.
In addition to the clinical assessment an objective measure of the effects of the drugs on central (cortical) arousal was carried out by measuring critical flicker fusion threshold (CFFT) (see table) . Of these patients, two complained of transient nausea which did not persist but no other significant side effects were encountered. Ten of the 11 patients were able to tolerate the maximum doses of oxpentifylline (1200 mg/day). This was a small sample of patients and as can be seen the results were variable. Although some patients were improved by the addition of oxpentifylline to their existing therapy, this followed no clear pattern and was not statistically significant (using the Wilcoxon signed rank test). However, eight patients experienced abnormal involuntary movements, or a striking worsening of movements if previously present, while on oxpentifylline. Dyskinetic movements were not altered in patients number 2 and 11 while on the active agent, and patient number 10 showed a reduction in respect to her dyskinesias. The latter was the only patient being treated with bromocriptine during the trial period. The significance of these results is discussed below. Oxpentifylline did not produce any significant change in critical flicker fusion threshold either in individual patients or when the group was considered as a whole.
Discussion
The results of this investigation demonstrate no change in the therapeutic response to levodopa either subjectively or objectively when oxpentifylline was added to the treatment regimen. There was, however, a significant increase in the incidence of abnormal involuntary movements during treatment with oxpentifylline. This drug therefore appears to have a differential effect on these two manifestations of levodopa treatment.
Oxpentifylline, in common with other xanthine derivatives, might be expected to have some degree of central stimulating effect. 16 However the results of the critical flicker fusion threshold test reveal no significant change in levels with oxpentifylline. Our patients did not report any symptoms that might be interpreted as indicative of an alerting or stimulating effect (insomnia, tremor, nervousness or agitation). We believe therefore that at the doses used the effects of oxpentifylline which we observed are not attribut-R B Godwin-Austen, J A Twomey, G Hanks, and J Higgins These results raise the important possibility of utilising the differential action of the two dopamine receptor types to avoid some of the late hypersensitivity phenomena (dyskinesias, dystonias and possibly "on-off" attacks) of dopa treatment. If a selective blocker of the Dl receptor could be identified-or a selective D2 agonist-these side effects might be avoidable.
We acknowledge with thanks the assistance of Mrs Barbara George for her secretarial help and Hoechst Chemicals for a supply of oxpentifylline and matching placebo.
Dr Ian Hindmarch kindly loaned the critical flicker fusion apparatus for which we were most grateful. 
